Massive losses but still giving another $29.7 M in stock bonuses
after hundreds of millions in stock bonuses to a few insiders last year. They are bleeding this company dry even though its sole product is only half a drug with a further 10% of profits given to UCLA, the inventor.
Yes, that's a real revelation at this point. Did you hear that revenues were almost double analysts' expectations? Oh, and they beat on earnings, too. This company is going tobe profitable much sooner than anyone had expected.